Capecitabine: A novel agent for the treatment of solid tumors

Anti-Cancer Drugs

Volumn 12, Issue 8, 2001, Pages 639-646

  Johnston, P G ^a   Kaye, S ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

5 Fluorouracil; Breast cancer; Capecitabine; Colorectal cancer; Fluoropyrimidines; Thymidine phosphorylase

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYTOTOXIC AGENT; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; TAXANE DERIVATIVE; THYMIDINE PHOSPHORYLASE;

ALOPECIA; BOLUS INJECTION; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; HUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; PRODRUGS;

EID: 0034856316     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200109000-00001     Document Type: Review

References (70)

1. 5-Fluoropyrimidines
2. Antimetabolites
3. Antimetabolites
4. Thymidylate synthethase - A target enzyme in cancer chemotherapy
5. Utilization of 5-fluoro-2′-deoxyuridine triphosphate and 5-fluoro-2′-deoxycytidine triphosphate in DNA synthesis by DNA polymerase and from calf thymus
6. Preliminary evidence that incorporation of 5-fluorouracil into RNA correlates with antitumor response
7. Cancer of the colon
8. Systemic treatment options in advanced colorectal cancer: Perspectives on combination 5-fluorouracil plus leucovorin
9. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
10. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial
11. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
12. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study
13. 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer
14. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study
15. 24h) with or without folinic acid (FA) vs. bolus 5-Fu/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): A randomized phase III study of the EORTC GITCCG and the AIO
16. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
17. Treatment of breast cancer
18. Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer
19. Current management of advanced breast cancer
20. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer
21. Colorectal cancer: The challenge
22. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcimona
23. Development of treatment for advanced colorectal cancer: Infusional 5-FU and the role of new agents
24. Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration, and cost comparisons
25. A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy
26. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer
27. A study of quality of life in cancer patients receiving palliative chemotherapy
28. Patient preferences for oral versus intravenous palliative chemotherapy
29. A randomized crossover trial comparing oral UFT (uracil/tegafur) + leucovorin (LV) and intravenous fluorouracil (FU) + LV for patient preference and pharmacokinetics in advanced colorectal cancer
30. Oral fluoropyrimidines in the treatment of colorectal cancer
31. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer
32. The oral fluorouracil prodrugs
33. A phase II study of S-1 in patients with advanced gastric cancer
34. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers
35. An early phase II clinical study of S-1 in patients with breast cancer
36. Early phase II study of S-1 in patients with advanced head and neck cancer
37. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors
38. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma
39. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil
40. Pharmacokinetic, oral bioavailability and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase
41. A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer
42. Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: A phase II study
43. Promising activity with eniluracil (776C85) and oral 5-fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer: A phase II study
44. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
45. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients
46. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts
47. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
48. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts
49. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models
50. Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: Relationship to the expression of thymidine phosphorylase
51. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts
52. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
53. A multicenter phase II trial of Xeloda™ (capecitabine) in taxane-refractory metastatic breast cancer
54. A randomized phase II study of Xeloda™ (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy
55. First-line capecitabine treatment for metastatic breast cancer (MBC): Updated data from a randomised phase II trial
56. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda® (capecitabine)
57. A phase III trial (S014796) of Xeloda™ (capecitabine) in previously untreated advanced/metastatic colorectal cancer
58. A phase III trial of Xeloda™ (capecitabine) in previously untreated advanced/metastatic colorectal cancer
59. Capecitabine as first-line treatment for metastatic colorectal cancer (CRC): Integrated results of 1207 patients (pts) from 2 randomized, phase III studies
60. Effective dose-modification (DM) scheme for the management of toxicities with capecitabine therapy: Data from metastatic colorectal cancer (mCRC) phase III trials
61. A phase 2 trial of Xeloda (capecitabine) in advanced or metastatic pancreatic cancer
62. A phase II trial of capecitabine in relapsed ovarian cancer
63. Phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer
64. Safety profile and preliminary efficacy of capecitabine (Xeloda®) in combination with oxaliplatin in patients with advanced or metastatic solid tumours: Results from a phase I study
65. Phase I study of capecitabine combined with standard radiotherapy in patients with rectal cancer
66. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies
67. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
68. Results of a large phase III trial of Xeloda®/Taxotere® combination therapy vs Taxotere® monotherapy in metastatic breast cancer (MBC) patients
69. Dose-finding study of capecitabine in combination with docetaxel and epirubicin in prior untreated advanced breast cancer patients
70. Combining gemcitabine (GEM) and capecitabine (CAP) in advanced pancreatic cancer. Results of a phase I trial